Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1189–1193. doi: 10.1128/aac.40.5.1189

A novel antiviral agent which inhibits the endonuclease of influenza viruses.

J E Tomassini 1, M E Davies 1, J C Hastings 1, R Lingham 1, M Mojena 1, S L Raghoobar 1, S B Singh 1, J S Tkacz 1, M A Goetz 1
PMCID: PMC163289  PMID: 8723464

Abstract

A novel anti-influenza virus compound, flutimide, was identified in extracts of a recently identified fungal species, Delitschia confertaspora (F. Pelaez, J.D. Polishook, M. Valldosera, and J.Guarro, Mycotaxon 50:115-122, 1994). The compound, a substituted 2,6-diketopiperazine, selectively inhibited the cap-dependent transcriptase of influenza A and B viruses and had no effect on the activities of other polymerases. Similar to the 4-substituted 2,4-dioxobutanoic acids, a series of transcriptase inhibitors which we described previously (J. Tomassini, H. Selnick, M.E. Davies, M.E. Armstrong, J. Baldwin, M. Bourgeois, J.Hastings, D. Hazuda, J. Lewis, W. McClements, G. Ponticello, E. Radzilowski, G. Smith, A. Tebben, and A. Wolfe, Antimicrob. Agents Chemother. 38:2827-2837, 1994), this inhibitor, which is a natural product, affected neither the initiation nor the elongation of influenza virus mRNA synthesis, but it specifically targeted the cap-dependent endonuclease of the transcriptase. Additionally, the compound was inhibitory to the replication of influenza A and B viruses in cell culture. The selective antiviral properties of this compound further demonstrate the utility of influenza virus endonuclease as a target of antiviral agents.

Full Text

The Full Text of this article is available as a PDF (242.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braam J., Ulmanen I., Krug R. M. Molecular model of a eucaryotic transcription complex: functions and movements of influenza P proteins during capped RNA-primed transcription. Cell. 1983 Sep;34(2):609–618. doi: 10.1016/0092-8674(83)90393-8. [DOI] [PubMed] [Google Scholar]
  2. Hastings J. C., Selnick H., Wolanski B., Tomassini J. E. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother. 1996 May;40(5):1304–1307. doi: 10.1128/aac.40.5.1304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hayden F. G., Hay A. J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992;176:119–130. doi: 10.1007/978-3-642-77011-1_8. [DOI] [PubMed] [Google Scholar]
  4. Nakagawa Y., Kimura N., Toyoda T., Mizumoto K., Ishihama A., Oda K., Nakada S. The RNA polymerase PB2 subunit is not required for replication of the influenza virus genome but is involved in capped mRNA synthesis. J Virol. 1995 Feb;69(2):728–733. doi: 10.1128/jvi.69.2.728-733.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Oxford J. S., Perrin D. D. Influenza RNA transcriptase inhibitors: studies in vitro and in vivo. Ann N Y Acad Sci. 1977 Mar 4;284:613–623. doi: 10.1111/j.1749-6632.1977.tb21995.x. [DOI] [PubMed] [Google Scholar]
  6. Patterson J. L., Holloway B., Kolakofsky D. La Crosse virions contain a primer-stimulated RNA polymerase and a methylated cap-dependent endonuclease. J Virol. 1984 Oct;52(1):215–222. doi: 10.1128/jvi.52.1.215-222.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Plotch S. J., Bouloy M., Ulmanen I., Krug R. M. A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell. 1981 Mar;23(3):847–858. doi: 10.1016/0092-8674(81)90449-9. [DOI] [PubMed] [Google Scholar]
  8. Rossier C., Patterson J., Kolakofsky D. La Crosse virus small genome mRNA is made in the cytoplasm. J Virol. 1986 May;58(2):647–650. doi: 10.1128/jvi.58.2.647-650.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rychlik W., Domier L. L., Gardner P. R., Hellmann G. M., Rhoads R. E. Amino acid sequence of the mRNA cap-binding protein from human tissues. Proc Natl Acad Sci U S A. 1987 Feb;84(4):945–949. doi: 10.1073/pnas.84.4.945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sakagami H., Kawazoe Y., Komatsu N., Simpson A., Nonoyama M., Konno K., Yoshida T., Kuroiwa Y., Tanuma S. Antitumor, antiviral and immunopotentiating activities of pine cone extracts: potential medicinal efficacy of natural and synthetic lignin-related materials (review). Anticancer Res. 1991 Mar-Apr;11(2):881–888. [PubMed] [Google Scholar]
  11. Sakagami H., Nagata K., Ishihama A., Oh-hara T., Kawazoe Y. Anti-influenza virus activity of synthetically polymerized phenylpropenoids. Biochem Biophys Res Commun. 1990 Nov 15;172(3):1267–1272. doi: 10.1016/0006-291x(90)91586-h. [DOI] [PubMed] [Google Scholar]
  12. Schwartz R. E., Giacobbe R. A., Bland J. A., Monaghan R. L. L-671,329, a new antifungal agent. I. Fermentation and isolation. J Antibiot (Tokyo) 1989 Feb;42(2):163–167. doi: 10.7164/antibiotics.42.163. [DOI] [PubMed] [Google Scholar]
  13. Shi L., Summers D. F., Peng Q., Galarz J. M. Influenza A virus RNA polymerase subunit PB2 is the endonuclease which cleaves host cell mRNA and functions only as the trimeric enzyme. Virology. 1995 Apr 1;208(1):38–47. doi: 10.1006/viro.1995.1127. [DOI] [PubMed] [Google Scholar]
  14. Strid S., Ekström C., Datema R. Comparison of foscarnet and foscarnet esters as anti-influenza virus agents. Chemotherapy. 1989;35(1):69–76. doi: 10.1159/000238638. [DOI] [PubMed] [Google Scholar]
  15. Tkacz J. S., Giacobbe R. A., Monaghan R. L. Improvement in the titer of echinocandin-type antibiotics: a magnesium-limited medium supporting the biphasic production of pneumocandins A0 and B0. J Ind Microbiol. 1993 Feb;11(2):95–103. doi: 10.1007/BF01583681. [DOI] [PubMed] [Google Scholar]
  16. Tomassini J., Selnick H., Davies M. E., Armstrong M. E., Baldwin J., Bourgeois M., Hastings J., Hazuda D., Lewis J., McClements W. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother. 1994 Dec;38(12):2827–2837. doi: 10.1128/aac.38.12.2827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ulmanen I., Broni B. A., Krug R. M. Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proc Natl Acad Sci U S A. 1981 Dec;78(12):7355–7359. doi: 10.1073/pnas.78.12.7355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yamashita M., Krystal M., Palese P. Comparison of the three large polymerase proteins of influenza A, B, and C viruses. Virology. 1989 Aug;171(2):458–466. doi: 10.1016/0042-6822(89)90615-6. [DOI] [PubMed] [Google Scholar]
  19. de la Luna S., Martínez C., Ortín J. Molecular cloning and sequencing of influenza virus A/Victoria/3/75 polymerase genes: sequence evolution and prediction of possible functional domains. Virus Res. 1989 Jun;13(2):143–155. doi: 10.1016/0168-1702(89)90012-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES